BioLineRx Ltd. is a biopharmaceutical development company dedicated to building a portfolio of products for addressing unmet medical needs or that have advantages over currently available therapies. The company’s current product portfolio consists of five clinical stage candidates, including BL-1021, an orally available small molecule for neuropathic pain.
The company announced today the final results of the Phase 1a study of BL-1021. In this study, it was demonstrated that a single administration of BL-1021 in the dose range examined was safe and well tolerated. There were no significant changes noted in vital signs, ECG or laboratory safety parameters at any dose when compared either to baseline measurements or to the placebo group. In addition, the drug demonstrated the potential for once daily oral administration.
The trial was a double-blind, placebo-controlled study performed at the Hadassah Clinical Research Center in Jerusalem, Israel, led by principal investigator Professor Yosef Caraco. The study’s goal was to assess the safety, tolerability and pharmacokinetics of a single administration of BL-1021 (between 10 mg and 80 mg) in healthy male subjects.
The CEO of BioLineRx, Dr. Kinneret Savitsky, commented on the trial results, “We are very encouraged by these results, Which indicate that BL-1021 has potential as an effective treatment for neuropathic pain with minimal side effects and requiring only once daily dosing.”
For additional information about BioLineRx and its portfolio of potential drug candidates, please visit the company’s website at www.biolinerx.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment